A Study to See Whether Two HIV Vaccines Are Safe and Can Prevent HIV Infection
A Phase I, Dose-Ranging Trial of the Pasteur Merieux Connaught (PMC) Oligomeric HIV-1 gp160MN/LAI-2 Vaccine Alone or Primed With Live Recombinant ALVAC-HIV (vCP205) in HIV Seronegative Adults
Sponsor: Walter Reed Army Institute of Research (WRAIR)
A PHASE1 clinical study on HIV Infections and HIV Seronegativity, this trial is completed. The trial is conducted by Walter Reed Army Institute of Research (WRAIR) and has accumulated 5 data snapshots since 1998. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE1
First recorded
Apr 1998
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Walter Reed Army Institute of Research (WRAIR)
For direct contact, visit the study record on ClinicalTrials.gov .